Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

N4-Pharma-infographic-Nuvec.pdf

As a result of recently completed initial testing in vitro on loaded Nuvec®  with two generic siRNA probes, N4 Pharma has created an infographic outlining the key results and detailing how Nuvec®  works to deliver multiple siRNA into the same cell.

With siRNA increasingly being used in the development of therapeutics, particularly in Oncology, the ability of Nuvec®  to deliver multiple payloads makes it a unique delivery platform for developing novel combination therapies for cancer and vaccine treatments.

In N4 Pharma’s new infographic, you can learn more about how Nuvec®  works and what its benefits are below.

The data – evidence based results